Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 197

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 197
---
)15.2228 — — 228 Issuance of common stock in connection with our equity award programs0.22 — — 2 Stock-based compensation—20 — — 20 Other comprehensive loss—— — (1)(1)Net loss—— (4)— (4)Balance at March 31, 202490.9 1,561 (853)(1)707 Issuance of common stock in connection with our equity award programs0.41 — — 1 Stock-based compensation—20 — — 20 Net loss—— (93)— (93)Balance at June 30, 202491.3$1,582 $(946)$(1)$635 Balance at December 31, 202492.2$1,617 $(1,132)$— $485 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' equity)13.6142 — — 142 Issuance of common stock in connection with our equity award programs0.1— — — — Stock-based compensation—16 — — 16 Net loss—— (112)— (112)Balance at March 31, 2025105.9 1,775 (1,244)— 531 Issuance of common stock in connection with our equity award programs0.53——3 Stock-based compensation—15——15 Net income——— —— Balance at June 30, 2025106.4$1,793 $(1,244)$— $549 

See accompanying notes.

4

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(unaudited)

Six Months EndedJune 30,20252024Cash flow from operating activitiesNet loss$(112)$(97)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense31 40 Depreciation and amortization5 5 Noncash lease expense3 4 Impairment of long-lived assets— 20 Amortization of discounts on marketable securities(7)(13)Other items, net— 1 Changes in operating assets and liabilities:Receivable from collaboration partners ($